PBS listing a world first, with all indications for Sprycel now reimbursed in Australia

29 July 2019

In Australia, newly-diagnosed patients aged 18 years and over with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) will now have affordable access to Sprycel (dasatinib) as a first line oral therapy, when this is integrated with chemotherapy, Bristol-Myers Squibb (NYSE: BMY) revealed on Sunday.

Patients with Ph+ALLwill be able to accessSprycel via Australia’s Pharmaceutical Benefits Scheme (PBS) from August 1.

This PBS listing for Sprycel marks a world first, as Australia is the only country with reimbursement approval in this setting. The listing represents a commitment by B-MS to providing more options for Australian clinicians treating rare cancers, particularly patients with limited treatment options, the US pharma major stated.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK